Manufacturer copay assistance · Remicade (J1745) · Janssen (Johnson & Johnson)
Eligible patients pay as… · Maximum benefit Up to $20,000/year — applies to copay, coinsurance, or deductible · Covers Remicade drug cost only — does NOT cover infusion administration cost
Published terms from the manufacturer. Per-patient eligibility is confirmed at enrollment.
This manufacturer program excludes government insurance. Foundation disease funds are the route instead — status shown as of each fund's last verification.
Run a benefits estimate for Remicade — the program's cap applies against the patient share CareCost calculates.
Yes — Janssen CarePath Savings Program (Remicade) from Janssen (Johnson & Johnson). Eligible patients pay as little as $5 per infusion. Commercial insurance is required; Medicare and Medicaid patients are not eligible.
Eligible patients pay as little as $5 per infusion Maximum benefit: Up to $20,000/year — applies to copay, coinsurance, or deductible. Covers Remicade drug cost only — does NOT cover infusion administration cost
Accepted insurance: commercial. Not eligible: medicare, medicaid, tricare, va, government.